IP Library Granted Patent US 11,129,859
Granted Patent B2
US 11,129,859 · App. 17/088,355 · Granted Sep 28, 2021

Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them

Inventor: Thomas Borody (Five Dock, AU)
Assignee: Finch Therapeutics Holdings LLC
A61K35/74A61K9/4891A61K35/24A61K35/742A61P1/12C12N1/00C12N1/20A61B10/0038A61K9/4875A61K2035/115A61M5/142A61M31/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,129,859
App. No.
17/088,355
Granted
Sep 28, 2021
Kind
B2
Abstract

The present disclosure provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for using them. Methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.

Claims (21)

1. A method comprising: receiving a stool or portion thereof from a human donor, wherein the stool or portion thereof comprises a community of uncultured fecal bacteria; mixing the stool or portion thereof with a saline solution to form a mixture; processing the mixture to collect the community of uncultured fecal bacteria; and selectively removing bacterial species from the community of uncultured fecal bacteria to produce a composition comprising bacterial strains of the phylum Firmicutes , wherein the composition further comprises a cryoprotectant.

2. The method of claim 1 , wherein the cryoprotectant is added to the composition after the selectively removing step.

3. The method of claim 1 , wherein the selectively removing step comprises centrifugation.

4. The method of claim 1 , wherein the cryoprotectant is glycerol.

5. The method of claim 1 , wherein the composition does not include rough particulate matter from the stool or portion thereof.

6. The method of claim 1 , further comprising encapsulating the composition in an acid-resistant capsule.

7. The method of claim 6 , wherein the composition is formulated as a liquid.

8. The method of claim 1 , wherein the proportion of bacteria from the phylum Firmicutes relative to non- Firmicutes bacteria in the composition is greater than such proportion in the stool or portion thereof.

9. The method of claim 1 , wherein the composition comprises less than 1.0% fecal non-floral material from the stool of the donor.

10. The method of claim 1 , wherein the composition does not contain viable Bacteroides.

11. The method of claim 1 , further comprising encapsulating the composition for delivery to the small intestine.

12. The method of claim 1 , wherein processing the mixture comprises homogenizing and filtering the mixture.

13. A method comprising: receiving a stool or portion thereof from a healthy human donor, wherein the stool or portion thereof comprises a collection of uncultured fecal bacteria; mixing the stool or portion thereof with a saline solution to form a mixture; homogenizing and filtering the mixture to separate rough particulate matter from the collection of uncultured fecal bacteria; and selectively removing bacteria from the collection of uncultured fecal bacteria to produce a composition comprising bacterial species of the phylum Firmicutes.

14. The method of claim 13 , wherein the composition further comprises a cryoprotectant.

15. The method of claim 14 , wherein the cryoprotectant comprises glycerol.

16. The method of claim 13 , further comprising encapsulating the composition in an acid-resistant capsule.

17. The method of claim 16 , wherein the composition is formulated as a liquid.

18. The method of claim 13 , wherein the proportion of bacteria from the phylum Firmicutes relative to non- Firmicutes bacteria in the composition is greater than such proportion in the stool.

19. The method of claim 13 , wherein the composition comprises less than 1.0% fecal non-floral material from the stool of the donor.

20. The method of claim 13 , wherein the composition does not contain viable Bacteroides.

21. The method of claim 13 , wherein the selectively removing step comprises centrifugation.

Assignments (3)
CHANGE OF NAME Recorded Dec 31, 2020
From: CRESTOVO HOLDINGS LLC
To: FINCH THERAPEUTICS HOLDINGS LLC
Reel/Frame 054883/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2020
From: BORODY, THOMAS J.
To: CRESTOVO LLC
Reel/Frame 054269/0810 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2020
From: CRESTOVO LLC
To: CRESTOVO HOLDINGS LLC
Reel/Frame 054269/0835 →
Priority Claims (1)
AU 2010903474 · Aug 4, 2010 · national
Continuity (18)
Continuation 17012533 · Sep 4, 2020
Continuation 16887630 · May 29, 2020
Continuation 16523726 · Jul 26, 2019
Continuation 16433437 · Jun 6, 2019
Continuation 16364144 · Mar 25, 2019
Continuation 16118400 · Aug 30, 2018
Continuation 15975456 · May 9, 2018
Continuation 17088355
Continuation 15975456 · May 9, 2018
Continuation 15950939 · Apr 11, 2018
Continuation 15782519 · Oct 12, 2017
Continuation 15093679 · Apr 7, 2016
Continuation 13813915
Provisional Application 61494363 · Jun 7, 2011
Provisional Application 61483487 · May 6, 2011
Provisional Application 61451087 · Mar 9, 2011
Provisional Application 61450099 · Mar 7, 2011
Related Publication 20210052673A1 · Feb 25, 2021
Cited By (1)
US 12,409,085